ReviewBiomedicines2022
The Role of Beta-Adrenergic Receptors in Depression and Resilience.
Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Adjunctive Pharmacotherapy for Major Depressive Disorder with Anxiety Symptoms: from Monoamines to Recent Clinical Evidence.CNS drugs · 2026Review
- Do sex and gender matter in the pharmacological treatment of depression?Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- A paraventricular hypothalamic control of social stress susceptibility by targeting brown adipose tissue β3 adrenoceptor.Communications biology · 2026Article
- Neurobiological mechanisms and brain network dysfunction in major depressive disorder: an integrative review.Frontiers in integrative neuroscience · 2026Review
- Sinus bradycardia after intravenous methylprednisolone pulse therapy in patients with thyroid-associated ophthalmopathy.Frontiers in pharmacology · 2026Article
- Transcutaneous Auricular Vagus Nerve Stimulation for Treating Emotional Dysregulation and Inflammation in Common Neuropsychiatric Disorders.Brain sciences · 2025Review
- Research Progress on the Pathogenesis of Post-Stroke Depression.ACS omega · 2025Review
- Mechanistic intersections between migraine and major depressive disorder.The journal of headache and pain · 2025Review
- Effects of Midazolam and Dexmedetomidine on Cognitive Dysfunction Following Open-Heart Surgery: A Comprehensive Review.Brain and behavior · 2025Review
- Interaction of the Vagus Nerve and Serotonin in the Gut-Brain Axis.International journal of molecular sciences · 2025Review
- Mechanisms of the effect of gut microbes on depression through the microbiota-gut-brain axis.Frontiers in nutrition · 2025Review
- Poor control of pain increases the risk of depression: a cross-sectional study.Frontiers in psychiatry · 2024Article
- Review
- Understanding the Mechanisms of Action and Effects of Drugs of Abuse.Molecules (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Norepinephrine is a catecholamine neurotransmitter that has been extensively implicated in the neurobiology of major depressive disorder (MDD). An accumulating body of evidence indicates that investigations into the action of norepinephrine at the synaptic/receptor level hold high potential for a better understanding of MDD neuropathology and introduce possibilities for developing novel treatments for depression. In this review article, we discuss recent advances in depression neuropathology and the effects of antidepressant medications based on preclinical and clinical studies related to beta-adrenergic receptor subtypes. We also highlight a beta-3 adrenergic receptor-involved mechanism that promotes stress resilience, through which antidepressant efficacy is achieved in both rodent models for depression and patients with major depression-an alternative therapeutic strategy that is conceptually different from the typical therapeutic approach in which treatment efficacy is achieved by reversing pathological alterations rather than by enhancing a good mechanism such as natural resilience. Altogether, in this review, we systematically describe the role of beta-adrenergic receptors in depression and stress resilience and provide a new avenue for developing a conceptually innovative treatment for depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.